newsfilter
← Latest News
PR Newswire·

Liminal BioSciences Reports First Quarter Financial Results 2023

GPR84 antagonist program and OXER1 antagonist program on track to meet previously stated milestones in 2023Closed March 31, 2023 with just over CAD26.9 million cash on hand, expecting to provide cash runway into early